BioSpace News Archive

Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business.

Theralink Technologies, a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, announced its support of George Mason University’s involvement in the White House Cancer Moonshot Initiative.

Perimeter Medical Imaging AI, Inc. today reported leadership changes, including the appointment of Suzanne Foster as Chair of its Board of Directors, effective immediately.

Chromatin comprises a complex mixture of DNA and proteins and forms the structural basis of chromosomes in the cellular nuclei.

Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced it has signed an agreement with a leading group ‎purchasing organization for national distribution of its cardiac monitoring solutions, Bioflux® and BiotresTM.

In recent years, filamentous fungi or molds have emerged as causative agents underlying life-threatening infections in immunocompromised individuals.

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has provided the LGS Foundation a $100,000 educational grant to assist in efforts to raise awareness of LGS and provide educational materials to the LGS community.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”) today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD).

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases